A patent currently prevents any generic Angeliq from being manufactured in the United States. The earliest expected date that a generic version of the medication could become available is in August 2017, when the patent expires. However, several companies may claim to sell a generic Angeliq product, but there is no way of knowing whether you are getting genuine Angeliq.
An Overview of Angeliq Generic
Angeliq® (drospirenone/estradiol) is a hormone replacement therapy medication approved for treating menopausal symptoms, such as hot flashes and vaginal dryness. Angeliq contains both an estrogen (estradiol) and a progestin (drospirenone), and is only approved for women who still have a uterus (who have not had a hysterectomy). Angeliq is the only hormone replacement therapy that contains drospirenone.
Angeliq is made by Bayer HealthCare Pharmaceuticals. It is currently under the protection of a patent that prevents any generic Angeliq from being manufactured in the United States. However, if you search the Internet for "generic Angeliq," you may find a number of companies selling it. The fact is that these medicines may be fake, substandard, and potentially dangerous. There may be generic Angeliq available from another country, but there is really no way of knowing if you are getting genuine Angeliq or not. You should not buy any generic Angeliq until there is an approved generic available.
When Will a Generic for Angeliq Be Available?
The first patent for Angeliq currently expires in August 2017. This is the earliest predictable date that a generic version of Angeliq could become available. However, there are other circumstances that could come up to extend or shorten the exclusivity period of Angeliq. This could include such things as lawsuits or other patents for specific Angeliq uses. Once Angeliq goes off patent, there may be several companies that manufacture a generic Angeliq drug.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed June 10, 2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click